Welgenaleucel

GENETIC2 trials

Sponsors

UWELL Biopharma

Conditions

B-cell Non-Hodgkin LymphomaLymphoma Leukemia

Phase 1

Study of Welgenaleucel (UWC19) in Patients With Relapsed or Refractory B-cell Lymphoma

UWELL BiopharmaB-cell Non-Hodgkin Lymphoma

Start: 2020-07-27End: 2021-12-31Target: 20Updated: 2021-01-22

Unknown Phase

Immunotherapy With CD19 CAR T-cells in Patients With Relapsed or Refractory CD19+ Leukemia and Lymphoma

CompletedNCT03811457

UWELL BiopharmaLymphoma Leukemia

Start: 2017-06-01End: 2018-12-31Updated: 2019-01-22